Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

References

• Niemeyer C M, Sallan S E. Acute Lymphoblastic Leukemia. Hematology of Infancy and Childhood, D G Nathan, S H Orkin. WB Saunders Company, Philadelphia 1998; 1245–1285
   Google Scholar
• Hoelzer D, Gokbuget N, Ottmann O, Pui C H, Relling M V, Appelbaum F R, et al. Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2002; 162–192
   PubMedGoogle Scholar
• Dillman R O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20: 3545–3557
   PubMed Web of Science ®Google Scholar
• Chen Y H, Tang Y M, Shen H Q, Song H, Yang S L, Shi S W, et al. The expression of CD19 in 210 cases of childhood acute leukemia and its significance. Zhonghua Er Ke Za Zhi 2004; 42: 188–191
   PubMedGoogle Scholar
• Czuczman M S, Dodge R K, Stewart C C, Frankel S R, Davey S R, Powell B L, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93: 3931–3939
   PubMed Web of Science ®Google Scholar
• Uckun F M, Jaszcz W, Ambrus J L, Fauci A S, Gajl-Peczalska K, Song C W, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988; 71: 13–29
   PubMed Web of Science ®Google Scholar
• Scheuermann R H, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995; 18: 385–397
   PubMed Web of Science ®Google Scholar
• Ghetie M A, May R D, Till M, Uhr J W, Ghetie V, Knowles P P, et al. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 1988; 48: 2610–2617
   PubMed Web of Science ®Google Scholar
• Dorken B, Moldenhauer G, Schwartz R, Pezzutto A. B cell differeniation antigens identified by monoclonal antibodies. Immunobiology 1983; 165: 253–254
   Web of Science ®Google Scholar
• Ghetie M A, Tucker K, Richardson J, Uhr J W, Vitetta E S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 2315–2320
   PubMed Web of Science ®Google Scholar
• Herrera L, Yarbrough S, Ghetie V, Aquino D B, Vitetta E S. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 2003; 17: 334–338
   PubMed Web of Science ®Google Scholar
• Sievers E L. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis 2003; 31: 7–10
   PubMed Web of Science ®Google Scholar
• Mulford D A, Jurcic J G. Antibody-based treatment of acute myeloid leukaemia. Exp Opin Biol Ther 2004; 4: 95–105
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004; 83: 201–205
   PubMed Web of Science ®Google Scholar
• Blattman J N, Greenberg P D. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200–205
   PubMed Web of Science ®Google Scholar
• Kaleem Z, Crawford E, Pathan M H, Jasper L, Covinsky M A, Johnson L R, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003; 127: 42–48
   PubMed Web of Science ®Google Scholar
• Ludwig W D, Reiter A, Loffler H, Gokbuget N, Hoelzer D, Riehm H, et al. Immunophenotypic features of childhood and adult acute lymphoblastic leukemia [ALL]: experience of the German multicentre trials ALL-BFM and GMALL. Leuk Lymphoma 1994; 13(Suppl 1)71–76
   PubMed Web of Science ®Google Scholar
• Pulczynski S, Boesen A M, Jensen O M. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood 1993; 81: 1549–1557
   PubMed Web of Science ®Google Scholar
• Stone M J, Sausville E A, Fay J W, Headlee D, Collins R H, Figg W D, et al. A phase I study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996; 88: 1188–1197
   PubMed Web of Science ®Google Scholar
• Ghetie M A, Tucker K, Richardson J, Uhr J W, Vitetta E S. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 1994; 84: 702–707
   PubMed Web of Science ®Google Scholar
• Messmann R A, Vitetta E S, Headlee D, Senderowicz A M, Figg W D, Schindler J, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain [dgA] and IgG-RFB4-dgA (Combotox) in patients with refractory CD19[+], CD22[+] B cell lymphoma. Clin Cancer Res 2000; 6: 1302–1313
   PubMed Web of Science ®Google Scholar
• Vitetta E S, Stone M, Amlot P, Fay J, May R, Till M, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 4052–4058
   PubMed Web of Science ®Google Scholar
• May R D, Vitetta E S, Moldenhauer G, Dorken B. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. Cancer Drug Deliv 1986; 3: 261–272
   PubMedGoogle Scholar
• Ghetie M A, Podar E M, Gordon B E, Pantazis P, Uhr J W, Vitetta E S. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int J Cancer 1996; 68: 93–96
   PubMed Web of Science ®Google Scholar
• Herrera L, Farah R A, Pellegrini V A, Aquino D B, Sandler E S, Buchanan G R, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000; 14: 853–858
   PubMed Web of Science ®Google Scholar
• Jansen B, Kersey J H, Jaszcz W B, Gunther R, Nguyen D P, Chelstrom L M, et al. Effective immunochemotherapy of human t[4;11] leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 1993; 7: 290–297
   PubMed Web of Science ®Google Scholar
• Liu C, Lambert J M, Teicher B A, Blattler W A, O'Connor R. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 1996; 87: 3892–3898
   PubMed Web of Science ®Google Scholar
• Ek O, Gaynon P, Zeren T, Chelstrom L M, Myers D E, Uckun F M. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk. Lymphoma 1998; 31: 143–149
   PubMed Web of Science ®Google Scholar
• O'Connor R, Liu C, Ferris C A, Guild B C, Teicher B A, Corvi C, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995; 86: 4286–4294
   PubMed Web of Science ®Google Scholar
• Shah S A, Halloran P M, Ferris C A, Levine B A, Bourret L A, Goldmacher V S, et al. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res 1993; 53: 1360–1367
   PubMed Web of Science ®Google Scholar